BRAF and cutaneous melanoma: The high level of plasticity and heterogeneity of metastatic cutaneous melanoma cells, as illustrated by the pathways providing the BRAF-i resistance of the innate BRAF-m cells, suggest that the successful treatment of this disease requires the combination of several therapies targeting different oncogenic pathways [27,28,29,30].